Drug
LY3023414 clinical trials
Also written LY3023414, WHO 10889 and Samotolisib.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 4
Eli Lilly and Company (5) · National Cancer Institute (NCI) (2) · Baylor Research Institute (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Ensartinib (1) · Erdafitinib (1) · Ivosidenib (1) · Larotrectinib (1) · Olaparib (1) · Palbociclib (1) · Selpercatinib (1) · Selumetinib sulfate (1)
Studies
Open first, then newest update. How each study uses LY3023414 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Samotolisib
- Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedPhase 2National Cancer Institute (NCI)NCT03213678Written as Samotolisib
- LY3023414 and Prexasertib in Metastatic Triple-negative Breast CancerCompletedPhase 2Baylor Research InstituteNCT04032080Written as Drug 1: LY3023414; Drug 2: Prexasertib
- Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02549989Written as LY3023414
- A Study of Enzalutamide and LY3023414 in Men With Prostate CancerCompletedPhase 2Eli Lilly and CompanyNCT02407054Written as LY3023414
- A Study of LY3023414 and Necitumumab in Squamous Lung CancerTerminatedPhase 2Eli Lilly and CompanyNCT02443337Written as LY3023414
- A Study of LY3023414 in Japanese Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT02536586Written as LY3023414
- A Study of LY3023414 Formulations and the Effect of FoodCompletedPhase 1Eli Lilly and CompanyNCT02818335Written as LY3023414 Reference Fasted
- A Study of [¹⁴C]-LY3023414 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02575703Written as [¹⁴C]-LY3023414
Given in every arm · 7 — LY3023414 is usual care beside what is tested
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT03675893Written as LY3023414
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Written as LY3023414
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedPhase 1Eli Lilly and CompanyNCT02784795Written as LY3023414
- A Study of LY3023414 in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01655225Written as LY3023414
- A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)CompletedPhase 1Eli Lilly and CompanyNCT02079636Written as LY3023414
- A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT02124148Written as LY3023414
- A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal AdenocarcinomaCompletedPhase 2Eli Lilly and CompanyNCT02981342Written as LY3023414
Codes
What other systems call LY3023414 · ClinicalTrials.gg INT000742
- MeSH (NLM) C000621566LY3023414One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621566 | LY3023414 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.